Erratum: Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial (The Lancet (2018) 391(10122) (748–757), (S014067361733297X) (10.1016/S0140-6736(17)33297-X));Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

The Lancet

Volumn 391, Issue 10122, 2018, Pages 748-757

  Powles, Thomas ^a   Durán, Ignacio ^b,c   van der Heijden, Michiel S ^d   Loriot, Yohann ^e   Vogelzang, Nicholas J ^f   De Giorgi, Ugo ^g   Oudard, Stéphane ^h   Retz, Margitta M ⁱ   Castellano, Daniel ^j   Bamias, Aristotelis ^k   Fléchon, Aude ^l   Gravis, Gwenaëlle ^m   Hussain, Syed ⁿ   Takano, Toshimi ^o   Leng, Ning ^p   Kadel, Edward E ^p   Banchereau, Romain ^p   Hegde, Priti S ^p   Mariathasan, Sanjeev ^p   Cui, Na ^p   Shen, Xiaodong ^p   Derleth, Christina L ^p   Green, Marjorie C ^p   Ravaud, Alain ^q   more..

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c Instituto de Biomedicina de Sevilla   (Spain)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^g DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^h HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

ⁱ TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^j HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^k UNIVERSITY OF ATHENS   (Greece)

^l CENTRE LÉON BÉRARD   (France)

^m INSTITUT PAOLI CALMETTES   (France)

ⁿ PLYMOUTH UNIVERSITY PENINSULA SCHOOLS OF MEDICINE AND DENTISTRY   (United Kingdom)

^o TORANOMON HOSPITAL   (Japan)

^p GENENTECH INC   (United States)

^q BORDEAUX UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATEZOLIZUMAB; DOCETAXEL; PACLITAXEL; PLATINUM; PROGRAMMED DEATH 1 LIGAND 1; VINFLUNINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TAXOID; VINBLASTINE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; ADVERSE OUTCOME; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; ASIA PACIFIC; ASTHENIA; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DYSGEUSIA; DYSPNEA; EUROPE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; ILEUS; IMMUNOCOMPETENT CELL; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; NORTH AMERICA; OVERALL SURVIVAL; PACIFIC OCEAN; PARESTHESIA; PATIENT SATISFACTION; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RISK FACTOR; SENSORY NEUROPATHY; STOMATITIS; SURVIVAL RATE; TRANSITIONAL CELL CARCINOMA; TREATMENT DURATION; VOMITING; ANALOGS AND DERIVATIVES; CARCINOMA; CLINICAL TRIAL; COMPARATIVE STUDY; MIDDLE AGED; MORTALITY; SECONDARY; TREATMENT OUTCOME; URINARY TRACT TUMOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA; FEMALE; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; TAXOIDS; TREATMENT OUTCOME; UROLOGIC NEOPLASMS; VINBLASTINE;

EID: 85038610974     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(18)32516-9     Document Type: Erratum

References (32)

1. National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer stat facts: bladder cancer. http://seer.cancer.gov/statfacts/html/urinb.html (accessed April 28, 2017).
2. Loehrer, PJ Sr, Einhorn, LH, Elson, PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10 (1992), 1066–1073.
3. von der Maase, H, Sengelov, L, Roberts, JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23 (2005), 4602–4608.
4. Bellmunt, J, Orsola, A, Leow, JJ, et al. Bladder cancer: ESMO practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 25:suppl 3 (2014), iii40–iii48.
5. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: bladder cancer. V5. https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf, 2017 (accessed Sep 7, 2017).
6. Bellmunt, J, Theodore, C, Demkov, T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 27 (2009), 4454–4461.
7. Choueiri, TK, Ross, RW, Jacobus, S, et al. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol 30 (2012), 507–512.
8. Sankin, A, Narasimhulu, D, John, P, Gartrell, B, Schoenberg, M, Zang, X, The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: what lies beneath the tip of the iceberg, PD-L1. Urol Oncol, 2017 published online May 8. DOI:10.1016/j.urolonc.2017.04.007.
9. Bellmunt, J, de Wit, R, Vaughn, DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376 (2017), 1015–1026.
10. Chen, DS, Mellman, I, Oncology meets immunology: the cancer-immunity cycle. Immunity 39 (2013), 1–10.
11. Herbst, RS, Soria, JC, Kowanetz, M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515 (2014), 563–567.
12. Powles, T, Eder, JP, Fine, GD, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515 (2014), 558–562.
13. McDermott, DF, Sosman, JA, Sznol, M, et al. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study. J Clin Oncol 34 (2016), 833–842.
14. Rittmeyer, A, Barlesi, F, Waterkamp, D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389 (2017), 255–265.
15. Balar, AV, Galsky, MD, Rosenberg, JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389 (2017), 67–76.
16. Rosenberg, JE, Hoffman-Censits, J, Powles, T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387 (2016), 1909–1920.
17. Frampton, GM, Fichtenholtz, A, Otto, GA, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 31 (2013), 1023–1031.
18. Chalmers, ZR, Connelly, CF, Fabrizio, D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med, 9, 2017, 34.
19. Fehrenbacher, L, Spira, A, Ballinger, M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387 (2016), 1837–1846.
20. Massard, C, Gordon, MS, Sharma, S, et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol 34 (2016), 3119–3125.
21. Plimack, ER, Bellmunt, J, Gupta, S, et al. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncol 18 (2017), 212–220.
22. Bellmunt, J, Mullane, SA, Werner, L, et al. Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Ann Oncol 26 (2015), 812–817.
23. Powles, T, Smith, K, Stenzl, A, Bedke, J, Immune checkpoint inhibition in metastatic urothelial cancer. Eur Urol 72 (2017), 477–481.
24. Chen, DS, Mellman, I, Elements of cancer immunity and the cancer-immune set point. Nature 541 (2017), 321–330.
25. Motzer, RJ, Escudier, B, McDermott, DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373 (2015), 1803–1813.
26. Castellano, D, Puente, J, de Velasco, G, et al. Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice. BMC Cancer, 14, 2014, 779.
27. Garcia-Donas, J, Font, A, Perez-Valderrama, B, et al. Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial. Lancet Oncol 18 (2017), 672–681.
28. Medioni, J, Di Palma, M, Guillot, A, Spaeth, D, Theodore, C, Efficacy and safety of vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the french multi-centre CURVE study. BMC Cancer, 16, 2016, 217.
29. Pistamaltzian, N, Tzannis, K, Pissanidou, V, et al. Treatment of relapsed urothelial bladder cancer with vinflunine: Real-world evidence by the hellenic genitourinary cancer group. Anticancer Drugs 27 (2016), 48–53.
30. Tecentriq (atezolizumab): package insert. 2017, Genentech, South San Francisco, CA.
31. Tecentriq (atezolizumab): summary of product characteristics. 2017, Roche Registration Limited, Welwyn Garden City, UK.
32. Carbone, DP, Reck, M, Paz-Ares, L, et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med 376 (2017), 2415–2426.